With great interest, we read the article by Seneschal et al1 describing 8 patients who experienced psoriasiform eruptions during anti–tumor necrosis factor therapy. These patients were patch tested with the European standard series and 2 anti–tumor necrosis factor molecules. One patient who had developed adalimumab-related psoriasiform plaques responded to the etanercept patch test with edema and vesicles after 48 hours. Day 8 readings showed a flare of dermatitis in half the patients.1,2
Lecluse LLA, Piskin G, Bos JD. The Use of Patch Tests in Determining Hypersensitivity to Etanercept and Infliximab. Arch Dermatol. 2008;144(8):1070–1071. doi:10.1001/archderm.144.8.1070-b
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: